Apellis Pharmaceuticals, Inc.
APLS • NASDAQ
Apellis Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Cedric Francois, with a market cap of $2.2B.
CEOCedric Francois
Next Earnings
Upcoming earnings announcement for Apellis Pharmaceuticals, Inc.
Date
Wednesday, May 6, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.38
Revenue Estimate
$202.1M
Earnings History
Past 12 earnings reports for Apellis Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | -$0.47Est: -$0.39 | -20.5% | $199.9MEst: $197.4M | +1.3% |  10-K |
| Oct 30, 2025 | Q3 2025 | $1.67Est: $0.98 | +70.4% | $458.6MEst: $392.0M | +17.0% | 10-Q |
| Jul 31, 2025 | Q2 2025 | -$0.33Est: -$0.46 | +28.3% | $178.5MEst: $188.4M | -5.3% | 10-Q |
| May 7, 2025 | Q1 2025 | -$0.74Est: -$0.34 | -117.6% | $166.8MEst: $197.6M | -15.6% | 10-Q |
| Feb 28, 2025 | Q4 2024 | -$0.29Est: -$0.40 | +27.5% | $212.5MEst: $197.9M | +7.4% | 10-K |
| Nov 5, 2024 | Q3 2024 | -$0.46Est: -$0.30 | -53.3% | $196.8MEst: $200.4M | -1.8% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.28Est: -$0.32 | +12.5% | $199.7MEst: $193.8M | +3.0% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.54Est: -$0.52 | -3.8% | $172.3MEst: $163.4M | +5.5% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$0.73Est: -$0.69 | -5.8% | $146.4MEst: $143.6M | +1.9% | 10-K/A |
| Nov 1, 2023 | Q3 2023 | -$1.17Est: -$0.85 | -37.6% | $110.4MEst: $99.7M | +10.7% | — |
| Jul 31, 2023 | Q2 2023 | -$1.02Est: -$1.32 | +22.7% | $95.0MEst: $70.3M | +35.2% | — |
| May 4, 2023 | Q1 2023 | -$1.56Est: -$1.46 | -6.8% | $44.8MEst: $26.1M | +71.8% | — |